US 12252493
Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
granted A61PA61P35/00
Quick answer
US patent 12252493 (Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer) held by Mirati Therapeutics, Inc. expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61P, A61P35/00